OBJECTIVES: Cytoplasmic clusterin (Clusterin), a ubiquitous multifunctional secretory sulfated glycoprotein, plays a role in apoptosis and is reportedly overexpressed in a variety of tumors. The role of Clusterin in pancreatic neuroendocrine tumors (PNETs) has not been investigated. In this study, Clusterin expression was evaluated in a subset of PNETs, and the results were correlated with the clinical-pathological features of the tumors. METHODS: Fifty-nine surgical cases were used to evaluate the immunohistochemical expression of Clusterin in PNETs. Using the avidin-biotin complex method, tissue sections from each case were stained with a rabbit anticlusterin antibody (Abcam, Cambridge, Mass). The immunohistochemical reactions were qualitatively and semiquantitatively evaluated by 2 pathologists. RESULTS: Strong Clusterin reactivity was identified in 36 (61%) of 59 PNETs. In 23 (39%) of 59 cases, the Clusterin score was 3 or less. Clusterin expression scores significantly associated with tumor size (P = 0.03) and with tumor stage (P = 0.02). The immunohistochemical score index did not correlate with tumor grade (P = 0.15). CONCLUSIONS: We report the expression of Clusterin in PNETs. The correlation of Clusterin with tumor size and stage suggests involvement of this molecule in pancreatic neuroendocrine tumor progression. Clusterin may represent a new target of therapy for PNETs.
OBJECTIVES: Cytoplasmic clusterin (Clusterin), a ubiquitous multifunctional secretory sulfated glycoprotein, plays a role in apoptosis and is reportedly overexpressed in a variety of tumors. The role of Clusterin in pancreatic neuroendocrine tumors (PNETs) has not been investigated. In this study, Clusterin expression was evaluated in a subset of PNETs, and the results were correlated with the clinical-pathological features of the tumors. METHODS: Fifty-nine surgical cases were used to evaluate the immunohistochemical expression of Clusterin in PNETs. Using the avidin-biotin complex method, tissue sections from each case were stained with a rabbit anticlusterin antibody (Abcam, Cambridge, Mass). The immunohistochemical reactions were qualitatively and semiquantitatively evaluated by 2 pathologists. RESULTS: Strong Clusterin reactivity was identified in 36 (61%) of 59 PNETs. In 23 (39%) of 59 cases, the Clusterin score was 3 or less. Clusterin expression scores significantly associated with tumor size (P = 0.03) and with tumor stage (P = 0.02). The immunohistochemical score index did not correlate with tumor grade (P = 0.15). CONCLUSIONS: We report the expression of Clusterin in PNETs. The correlation of Clusterin with tumor size and stage suggests involvement of this molecule in pancreatic neuroendocrine tumor progression. Clusterin may represent a new target of therapy for PNETs.
Authors: Dan Xie; Sze Hang Lau; Jonathan S T Sham; Qiu-Liang Wu; Yan Fang; Li-Zhi Liang; Li-Hong Che; Yi-Xin Zeng; Xin-Yuan Guan Journal: Cancer Date: 2005-01-15 Impact factor: 6.860
Authors: Cristina R Ferrone; Laura H Tang; James Tomlinson; Mithat Gonen; Steven N Hochwald; Murray F Brennan; David S Klimstra; Peter J Allen Journal: J Clin Oncol Date: 2007-12-10 Impact factor: 44.544
Authors: J Steinberg; R Oyasu; S Lang; S Sintich; A Rademaker; C Lee; J M Kozlowski; J A Sensibar Journal: Clin Cancer Res Date: 1997-10 Impact factor: 12.531
Authors: Thomas W Czeczok; Kristen M Stashek; Jessica E Maxwell; Thomas M O'Dorisio; James R Howe; Jason L Hornick; Andrew M Bellizzi Journal: Appl Immunohistochem Mol Morphol Date: 2018-02
Authors: Pål Vange; Torunn Bruland; Berit Doseth; Reidar Fossmark; Mirta M L Sousa; Vidar Beisvag; Øystein Sørdal; Gunnar Qvigstad; Helge L Waldum; Arne K Sandvik; Ingunn Bakke Journal: PLoS One Date: 2017-09-13 Impact factor: 3.240